

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No. : PCT/EP00/00776
 International Filing Date : 1 FEBRUARY 2000 #10
 U.S. Serial No. : 09/868,569
 Deposit Date U.S. Nat'l Phase : 20 JUNE 2001
 Priority Date(s) Claimed : 1 FEBRUARY 1999
 Applicant(s) : CHRISTOPHERS, Enno, et al.
 Title: HUMAN ANTIBIOTIC PROTEINS

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE
 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 11213-1450

Sir:


In response to the Notification of Defective Response dated 22 SEPTEMBER 2003:

- ☐ Attached is a Declaration and Power of Attorney in compliance with 37 CFR § 1.53 along with the late filing surcharge of \$65.00/\$130.00
- ☐ Applicant(s) include an executed assignment and Recordation Form Cover Sheet with the recordation fee of \$40.00 (Check No.).
- ☒ Attached is a copy of the Notification of Defective Response.
- ☐ Applicant(s) request that the time for taking action in this case be extended pursuant to 37 CFR 1.136(a) for a period of one/two/three/four/five month(s) along with the fee of \$110.00/\$410.00/\$930.00/\$1450.00/\$1970.00.
- ☐ Applicant(s) are entitled to small entity status.
- ☐ Attached is a verified English translation of the PCT publication along with the fee of \$130.00.
- ☐ Attached is a Preliminary Amendment.
- ☐ Applicant(s) include the extra claims fee of \$ for claims in excess of 20 \$18/\$9 per additional claim, for independent claims in excess of 3 \$84/\$42 per additional claim, and/or \$280 for multiple dependent claims.
- ☒ Attached is the Sequence Disclosure (paper/disk versions) with the appropriate statement as required.
- ☐ Attached is an Application Data Sheet (ADS).

☐ Attached are the substitute drawings as required.

Attached is a check in the amount of \$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,



Anthony J. Zelano
Registration No. 27,969
Attorney/Agent for Applicants


MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703)243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1813A

Date: 9 OCTOBER 2003



UNITED STATES PATENT AND TRADEMARK OFFICE



U.S. APPLICATION NUMBER NO. 09/868,569	FIRST NAMED APPLICANT ENNO CHRISTOPHERS	ATTY. DOCKET NO. SCH-1813(A)-33808F150
INTERNATIONAL APPLICATION NO. PCT/EP00/00776		

23599
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

LA. FILING DATE 02/01/2000	PRIORITY DATE
-------------------------------	---------------

CONFIRMATION NO. 1492

371 FORMALITIES LETTER



OC000000007383472

Date Mailed: 01/30/2002

*Missing Reg. (1) Mo.
x 100 Eof. Due- 2/19/02
(See Below)*

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fee
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Translation of the application into English. The current translation of the application into English is defective as described below.
 - The text in the drawings has not been properly translated.
 - The number of claims in the International Application and the number of claims in the translation are not the same.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

Dkt'd 2/11/02-LR

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended up to a maximum of six months.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/868,569	PCT/EP00/00776	33808F150